Poseida, Takeda Aim to Develop Non-viral Gene Therapies for Hemophilia

Poseida, Takeda Aim to Develop Non-viral Gene Therapies for Hemophilia

Hemophilia News Today

Image

Please enable the javascript to submit this form

Supported by educational grants from Bayer, BioMarin, Freeline Therapeutics Limited, Pfizer Inc., Shire, Spark Therapeutics, and uniQure, Inc.

Essential SSL